{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:05:59Z","timestamp":1790237159509,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.medj.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T19:24:47Z","timestamp":1591385087000},"page":"114-127.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"title":["Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19"],"prefix":"10.1016","volume":"1","author":[{"given":"Joseph","family":"Magagnoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9220-8049","authenticated-orcid":false,"given":"Siddharth","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-7157","authenticated-orcid":false,"given":"Tammy H.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Scott","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakrishna","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2020.06.001_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in\u00a0vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.medj.2020.06.001_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.medj.2020.06.001_bib3","series-title":"Fact sheet for health care providers: emergency use authorization (EUA) of hyroxychlroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","author":"Chorin","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2020.06.001_bib5","first-page":"215","article-title":"A pilot study of hydroxychloroquine in\u00a0treatment of patients with moderate COVID-19","volume":"49","author":"Chen","year":"2020","journal-title":"J.\u00a0Zhejiang Univ. (Med. Sci.)"},{"key":"10.1016\/j.medj.2020.06.001_bib6","doi-asserted-by":"crossref","first-page":"m1844","DOI":"10.1136\/bmj.m1844","article-title":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","volume":"369","author":"Mah\u00e9vas","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2020.06.001_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1787","article-title":"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit","author":"Bessi\u00e8re","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.medj.2020.06.001_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.medj.2020.06.001_bib9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.abc1731","article-title":"Against pandemic research exceptionalism","volume":"368","author":"London","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.medj.2020.06.001_bib10","series-title":"Fact sheet for patients and parent\/caregivers: emergency use authorization (EUA) of remdesivir for coronavirus disease 2019 (COVID-19)","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib11","article-title":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19","author":"Magagnoli","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.medj.2020.06.001_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","author":"Geleris","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2020.06.001_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2020.06.001_bib14","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2020.06.001_bib15","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2020.06.001_bib16","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2020.06.001_bib17","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2020.06.001_bib18","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2020.06.001_bib19","series-title":"Sermo reports jury is still out on Remdesivir; 31% of physicians who have used Remdesivir rate it as highly effective; 31% rate it with low effectiveness; 38% rate it as somewhere in the middle","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/03009747409115809","article-title":"Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine","volume":"3","author":"Laaksonen","year":"1974","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.medj.2020.06.001_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers","volume":"27","author":"Tett","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.medj.2020.06.001_bib22","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.medj.2020.06.001_bib23","series-title":"A randomized controlled clinical trial: hydroxychloroquine for the treatment of COVID-19 in hospitalized patients (OAHU-COVID19)","author":"Seto","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib24","series-title":"ALBERTA HOPE COVID-19 for the prevention of severe COVID19 disease","author":"Hill","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib25","series-title":"Efficacy and safety of hydroxychloroquine for treatment of COVID-19","author":"Lu","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib26","series-title":"Evaluation of the efficacy of the hydroxychloroquine-azithromycin combination in the in the prevention of COVID-19 related SDRA (TEACHCOVID)","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib27","series-title":"Outcomes related to COVID-19 treated with hydroxychloroquine among in-patients with symptomatic disease (ORCHID)","author":"Thompson","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib28","series-title":"Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection","author":"Stout","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib29","series-title":"Randomized comparison of combination azithromycin and hydroxychloroquine vs. hydroxychloroquine alone for the treatment of confirmed COVID-19","author":"Hussain","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib30","series-title":"Profile of veterans: 2017","year":"2017"},{"key":"10.1016\/j.medj.2020.06.001_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 \u2014 COVID-NET, 14 states, March 1\u201330, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.medj.2020.06.001_bib32","doi-asserted-by":"crossref","DOI":"10.1377\/hlthaff.2020.00598","article-title":"Disparities in outcomes among COVID-19 patients in a large health care system in California","author":"Azar","year":"2020","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.medj.2020.06.001_bib33","series-title":"FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib34","series-title":"Coronavirus Disease 2019 (COVID-19)Treatment Guidelines","year":"2020"},{"key":"10.1016\/j.medj.2020.06.001_bib35","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2020.06.001_bib36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1541-0420.2009.01287.x","article-title":"Statistical methods for analyzing right-censored length-biased data under cox model","volume":"66","author":"Qin","year":"2010","journal-title":"Biometrics"},{"key":"10.1016\/j.medj.2020.06.001_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/pds.3727","article-title":"Performance of time-dependent propensity scores: a pharmacoepidemiology case study","volume":"24","author":"Ray","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.medj.2020.06.001_bib38","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/10543406.2019.1657138","article-title":"Performance evaluation of regression splines for propensity score adjustment in post-market safety analysis with multiple treatments","volume":"29","author":"Tian","year":"2019","journal-title":"J.\u00a0Biopharm. Stat."},{"key":"10.1016\/j.medj.2020.06.001_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/sim.5884","article-title":"Bias associated with using the estimated propensity score as a regression covariate","volume":"33","author":"Hade","year":"2014","journal-title":"Stat. Med."},{"key":"10.1016\/j.medj.2020.06.001_bib40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/biom.12505","article-title":"Propensity score matching and subclassification in observational studies with multi-level treatments","volume":"72","author":"Yang","year":"2016","journal-title":"Biometrics"},{"key":"10.1016\/j.medj.2020.06.001_bib41","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/pds.968","article-title":"On principles for modeling propensity scores in medical research","volume":"13","author":"Rubin","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634020300064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634020300064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:54:04Z","timestamp":1763002444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634020300064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2666634020300064"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2020.06.001","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.16.20065920","asserted-by":"object"}]},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}